MedTrace Logo

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

NCT03162783 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2025-01-16

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects with dry eye syndrome.

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

ADX-102 Ophthalmic Solution (0.5%)

ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.

DRUG

ADX-102 Ophthalmic Solution (0.1%)

ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.

DRUG

ADX-102 Ophthalmic Lipid Solution (0.5%)

ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.

Sponsors & Collaborators

  • Aldeyra Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-15
Primary Completion
2017-07-06
Completion
2017-07-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03162783 on ClinicalTrials.gov